Brain

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

Retrieved on: 
Friday, March 22, 2024
Brain, Taste, Nitisinone, Partnership, Education, Patient, PKU, Phenylalanine, DSM-IV codes, Insurance, Protein, APR, Diet, Homocystinuria, Patent, OTCQB, FDA, Practitioner, Pharmaceutical industry

After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated $100 million U.S. PKU medical formula market.

Key Points: 
  • After extensive discussions with metabolic geneticists, dieticians, and PKU patients, we believe PKU GOLIKE is the best product in the estimated $100 million U.S. PKU medical formula market.
  • PKU GOLIKE’s taste-masked, odor-free coating technology is designed to provide a better taste and a superior experience compared to alternative PKU medical formulas.
  • Relief launched PKU GOLIKE Granules in the United States in the fourth quarter of 2022 and the PKU GOLIKE Tropical Bar in the second quarter of 2023.
  • Eton plans to promote PKU GOLIKE with its existing metabolic sales force, which currently promotes Eton’s Carglumic Acid, Betaine, and Nitisinone products.

Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain

Retrieved on: 
Thursday, March 21, 2024
Psilocybin, University of Guelph, Research, Certification, Brain, Learning, University, Memory, Associate, Partnership, Patient, Knowledge, Fungus, Agriculture, Anxiety, Adolescence, Autism spectrum, Biomedical sciences, Spectrum, ASD, Biomass, Pharmaceutical industry

This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.

Key Points: 
  • This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
  • The collaborative preclinical research will focus on exploring and standardizing the chemical diversity of Rose Hill’s psilocybin mushrooms, legally imported from Jamaica to Canada for the work.
  • Additionally, utilizing a rodent model, the study will investigate their potential application in Autism Spectrum Disorders (ASD).
  • Psilocybin mushrooms, known for their psychoactive properties, have long captivated the scientific community's interest due to their potential therapeutic applications and unique biochemical composition.

University of South Florida research funding reaches record high of $692 million

Retrieved on: 
Wednesday, March 20, 2024
Rhea, College, Health, Corps, Brain, Organization, Growth, Alzheimer's disease, National Science Foundation, University, Insomnia, Knowledge, Research, Sleep, Bird, Engineer, Chronic pain, AAAS, NIH, Water, USF, Bangladesh Technical Education Board, Spectrum, Disorder

“The University of South Florida's record-breaking success in research funding is a reflection of our commitment to advancing new knowledge, fostering innovation and making a positive impact on society," USF President Rhea Law said.

Key Points: 
  • “The University of South Florida's record-breaking success in research funding is a reflection of our commitment to advancing new knowledge, fostering innovation and making a positive impact on society," USF President Rhea Law said.
  • "The dedicated work of our world-class faculty, talented research staff and collaborative partners continues to lift USF’s research enterprise to new heights."
  • USF’s funding from private partnerships grew by 11% to $218 million, while funding from state and local sources nearly doubled to $82 million.
  • “This substantial increase in research enterprise funding reflects USF’s stature as a top public research university,” said Sylvia Wilson Thomas, USF vice president for research and innovation.

DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO

Retrieved on: 
Wednesday, March 20, 2024
Health, Brain, Dementia, Sport, Acceleration, Intelligence, BRAIN, Mental health, Research, CIPO, University, Hamilton Health Sciences, Drexel University

The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S.

Key Points: 
  • The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S.
  • CERVAI™ Brain Health AI Platform is a world-first consumer brain health and wellness AI solution that estimates BRAIN AGE® and provides a brain health score.
  • Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a BRAIN AGE® Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.
  • Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Retrieved on: 
Tuesday, March 19, 2024
HER2, Acute leukemia, Exercise, Index, Exchange, Colorectal cancer, MMR, Memorial, Headache, Patient, Research, Diarrhea, Brain, CML, KOL, Aes, Sale, Cancer, Security (finance), IND, MBA, Prospectus, MBC, Nausea, Therapy, CRC, PIPE, Pharmacokinetics, MTD, Food, Pharmaceutical industry

BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.

Key Points: 
  • “The additional funding further strengthens our balance sheet and enables us to achieve critical, longer-term clinical milestones as we advance our parallel lead programs, ELVN-001 and ELVN-002.
  • Enliven anticipates the gross proceeds from the private placement to be approximately $90 million, before deducting offering expenses.
  • The PIPE financing is expected to close on or about March 21, 2024, subject to satisfaction of customary closing conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Retrieved on: 
Tuesday, March 19, 2024
Ornithine, Brain, PTC Therapeutics, Partnership, Deficiency, Patient, Death, Life, Therapy, Spine, PTC, FDA, AADC, BLA, Food, Pharmaceutical industry

If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.

Key Points: 
  • If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.
  • “AADC Deficiency is a devastating rare pediatric movement disorder that causes significant developmental delays and autonomic symptoms starting from birth.
  • Patients with AADC deficiency are at a high risk of death in the first decade of life,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
  • Through our partnership with PTC, we are demonstrating our commitment to drive progress for the AADC Deficiency community.”

NFA Labs, Creator of ‘Athena GPT’, Announces Staggering $71k Profit Made By It’s AI Neural Network In Only 8 Days

Retrieved on: 
Tuesday, March 19, 2024
Intelligence, Ecosystem, Machine learning, Uncertainty, Brain, ATH, Research, Decentralized finance, GPT, Fear, Cryptocurrency

In 2023, one of those companies, NFA Labs, set out on a mission to develop a cutting-edge trading algorithm that mimics the intricate workings of the human brain.

Key Points: 
  • In 2023, one of those companies, NFA Labs, set out on a mission to develop a cutting-edge trading algorithm that mimics the intricate workings of the human brain.
  • The company says that Athena has the ability to trade across unlimited tokens and exchanges, and has proven to have amazing accuracy.
  • When NFA Labs first launched their cryptocurrency token “NFAi”, savvy investors flocked to the vision the company had, and what they were building.
  • Now that “AI” has pushed the financial sector into a bull market, it’s expected that NFA Labs and its ecosystem is about to get many new eyes on it.

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

Retrieved on: 
Tuesday, March 19, 2024
Brain, IBN, ALS, CNM, Patient, Mitochondrion, Nanotechnology, Interview

LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN) , recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.

Key Points: 
  • LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN) , recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.
  • During the interview, Etherington highlighted information about Clene’s work in the field of nanotechnology.
  • “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood.
  • We then proceeded into two amyotrophic lateral sclerosis (ALS) studies and one multiple sclerosis study, all of which have concluded in the past 18 months.

AutoScheduler CEO Keith Moore Discusses Warehouse Trends, Innovation, and Entrepreneurship

Retrieved on: 
Tuesday, March 19, 2024
National Instruments, Automation, Brain, COVID, Warehouse management system, Sale, Running, Robotics, Software, Human, Gambling, Walmart, Innovation system, Machine learning, WMS

AUSTIN, Texas, March 19, 2024 (GLOBE NEWSWIRE) -- Keith Moore, CEO of AutoScheduler.AI , an innovative Warehouse Management System (WMS) accelerator, discusses with Joe Rule on a Bold Visions podcast, current warehouse trends, and Keith’s entrepreneurial journey.

Key Points: 
  • AUSTIN, Texas, March 19, 2024 (GLOBE NEWSWIRE) -- Keith Moore, CEO of AutoScheduler.AI , an innovative Warehouse Management System (WMS) accelerator, discusses with Joe Rule on a Bold Visions podcast, current warehouse trends, and Keith’s entrepreneurial journey.
  • "Logistics technology has gotten extremely popular since COVID," says Keith Moore, CEO of AutoScheduler.AI.
  • Then his dad, Tom Moore, CEO and Founder of ProvisionAi, told him about a tool he built while consulting for P&G.
  • AutoScheduler, a warehouse resource optimization platform, manages all the work coming in and out of the warehouse to streamline operations and improve efficiencies.